Skip to content

Electrical stimulation of sphenopalatine ganglion for treatment of migraine: An exploratory study

Electrical stimulation of sphenopalatine ganglion for treatment of migraine: An exploratory study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500107565
Enrollment
Unknown
Registered
2025-08-14
Start date
2025-08-18
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine

Interventions

Treatment group:Electrical stimulation of the sphenopalatine ganglion

Sponsors

Shenzhen Nanshan People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.Subjects were between the ages of 18 and 70, male and female, mentally normal and conscious. 2.Subjects had no abnormalities on cranial MRI or CT, no previous history of head trauma, and a negative neurological examination. 3.Subjects were diagnosed as suffering from migraine with or without aura according to 2018 ICHD-3 diagnostic criteria 1.1 and 1.2.1.1. 4.Subjects had a MIDAS grade of III or IV, or a HIT-6 score > 56. 5.Subjects agree not to participate in complementary or alternative treatments during the baseline or treatment phase of the clinical study. This includes: acupuncture, TENS and magnetic field therapy.

Exclusion criteria

Exclusion criteria: 1. Subjects had been diagnosed with TACs or a history of trigeminal neuralgia. 2. Subjects had undergone SPG block or radiofrequency ablation within the past 3 months. 3. Subjects had received head and neck botulinum toxin A injections or CGRP inhibitors within the past 3 months. 4. Subjects with preoperative puncture site infections or coagulation disorders. 5. Subjects were women of childbearing age who were pregnant, breastfeeding or not using contraception. 6. Subjects who, in the judgement of the investigator, are unsuitable for the study for any reason.

Design outcomes

Primary

MeasureTime frame
Changes in number of migraine days per month relative to baseline;

Secondary

MeasureTime frame
Changes in Migraine Disability Assessment (MIDAS) questionnaire scores;Safety;Changes in headache severity;Changes in headache impact test (HIT-6) scores;Changes in headache duration;Changes in pittsburgh sleep quality index (PSQI) scores;Changes in frequency of headache attacks;Use of pain medication;

Countries

China

Contacts

Public ContactYuhui Luo

Shenzhen Nanshan People's Hospital

463387638@qq.com+86 134 8012 9949

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026